Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 174

1.

Central venous access device-related infections in patients with haemophilia.

Yeoh ZH, Furmedge J, Ekert J, Crameri J, Curtis N, Barnes C.

J Paediatr Child Health. 2013 Mar;49(3):242-5. doi: 10.1111/jpc.12112. Epub 2013 Feb 26.

PMID:
23438133
2.

Central venous access devices in haemophilia.

Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM.

Haemophilia. 2004 Mar;10(2):134-46. Review.

PMID:
14962202
3.

Surveillance of infectious complications associated with central venous access devices in children with haemophilia.

Tarantino MD, Lail A, Donfield SM, Lynn H, Peddle L, Hunsberger S, Shapiro AD.

Haemophilia. 2003 Sep;9(5):588-92.

PMID:
14511299
4.

Central venous access devices for paediatric patients with haemophilia: a single-institution experience.

Titapiwatanakun R, Moir C, Pruthi RK, Stavlo PL, Schmidt KA, Rodriguez V.

Haemophilia. 2009 Jan;15(1):168-74. doi: 10.1111/j.1365-2516.2008.01906.x.

PMID:
19149849
5.

Monthly recombinant tissue plasminogen activator administration to implantable central venous access devices decreases infections in children with haemophilia.

Jeng MR, O'Brien M, Wong W, Zoland J, Lea J, Tang N, Glader B.

Haemophilia. 2009 Nov;15(6):1272-80. doi: 10.1111/j.1365-2516.2009.02063.x. Epub 2009 Jul 10.

PMID:
19601989
6.

Experience with central venous access devices (CVADs) in the Canadian hemophilia primary prophylaxis study (CHPS).

Langley AR, Stain AM, Chan A, McLimont M, Chait S, Wu J, Poon MC, Card R, Israels SJ, Laferriere N, Klaassen RJ, Rivard GE, Cloutier S, Hawes S, Feldman B, Blanchette V.

Haemophilia. 2015 Jul;21(4):469-76. doi: 10.1111/hae.12713.

PMID:
26104147
7.

Central venous access device infections in children with hemophilia: a comparison of prophylaxis and episodic therapy.

Hacker MR, Page JH, Shapiro AD, Rich-Edwards JW, Manco-Johnson MJ.

J Pediatr Hematol Oncol. 2007 Jul;29(7):458-64.

PMID:
17609623
8.

Overview of the use of implantable venous access devices in the management of children with inherited bleeding disorders.

Komvilaisak P, Connolly B, Naqvi A, Blanchette V.

Haemophilia. 2006 Dec;12 Suppl 6:87-93. Review.

PMID:
17123400
9.

Central venous access devices in children with congenital coagulation disorders: complications and long-term outcome.

McMahon C, Smith J, Khair K, Liesner R, Hann IM, Smith OP.

Br J Haematol. 2000 Aug;110(2):461-8.

PMID:
10971409
10.

Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study.

Rodriguez V, Mancuso ME, Warad D, Hay CR, DiMichele DM, Valentino L, Kenet G, Kulkarni R.

Haemophilia. 2015 Sep;21(5):e369-74. doi: 10.1111/hae.12740. Epub 2015 Jul 14.

PMID:
26178581
11.

Long-term results of central venous access devices in children with haemophilia.

Upadhyaya M, Richards M, Buckham S, Squire BR.

Pediatr Surg Int. 2009 Jun;25(6):503-6. doi: 10.1007/s00383-009-2380-4. Epub 2009 May 20.

PMID:
19455342
12.

Complications associated with central venous access device in children with haemophilia: a nationwide multicentre study in Finland.

Vepsäläinen K, Lassila R, Arola M, Lähteenmäki P, Möttönen M, Mäkipernaa A, Riikonen P.

Haemophilia. 2015 Nov;21(6):747-53. doi: 10.1111/hae.12665. Epub 2015 Mar 31.

PMID:
25832453
13.

Incidence of catheter-associated bloodstream infection after introduction of minocycline and rifampin antimicrobial-coated catheters in a pediatric burn population.

Weber JM, Sheridan RL, Fagan S, Ryan CM, Pasternack MS, Tompkins RG.

J Burn Care Res. 2012 Jul-Aug;33(4):539-43. doi: 10.1097/BCR.0b013e31823c4cd5.

PMID:
22210071
14.

MRI after removal of central venous access device reveals a high number of asymptomatic thromboses in children with haemophilia.

Ranta S, Kalajoki-Helmiö T, Pouttu J, Mäkipernaa A.

Haemophilia. 2012 Jul;18(4):521-6. doi: 10.1111/j.1365-2516.2011.02719.x. Epub 2011 Dec 19.

PMID:
22176603
15.

Complications of central venous access devices in paediatric haemophilia patients.

Domm JA, Hudson MG, Janco RL.

Haemophilia. 2003 Jan;9(1):50-6.

PMID:
12558778
16.

Infection related to implantable central venous access devices in cancer patients: epidemiology and risk factors.

Freire MP, Pierrotti LC, Zerati AE, Araújo PH, Motta-Leal-Filho JM, Duarte LP, Ibrahim KY, Souza AA, Diz MP, Pereira J, Hoff PM, Abdala E.

Infect Control Hosp Epidemiol. 2013 Jul;34(7):671-7. doi: 10.1086/671006. Epub 2013 May 21.

PMID:
23739070
17.

Consensus recommendations for use of central venous access devices in haemophilia.

Ewenstein BM, Valentino LA, Journeycake JM, Tarantino MD, Shapiro AD, Blanchette VS, Hoots WK, Buchanan GR, Manco-Johnson MJ, Rivard GE, Miller KL, Geraghty S, Maahs JA, Stuart R, Dunham T, Navickis RJ.

Haemophilia. 2004 Sep;10(5):629-48. Review.

PMID:
15357790
18.

Surveillance methods for central venous access device-associated infections in Canadian pediatric hospitals.

Langley JM, LaRoche L, Hanakowski M.

Can J Infect Control. 1995 Autumn;10(3):80-2.

PMID:
8555515
19.
20.

Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience.

Neunert CE, Miller KL, Journeycake JM, Buchanan GR.

Haemophilia. 2008 Mar;14(2):260-70. doi: 10.1111/j.1365-2516.2007.01605.x. Epub 2007 Dec 28. Review.

PMID:
18179577
Items per page

Supplemental Content

Write to the Help Desk